compound introduction
BRD5648 ((R)-BRD0705) is a negative control of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC 50 of 66 nM and a K d of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC 50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML). In Vitro BRD5648, the inactive enantiomer of BRD0705, does not induce changes in enzyme phosphorylation or total β-catenin protein stabilization. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
